Skip to content

TrendMD’s recommendation engine now reaches 70 STEM publishers, 12 million readers

TrendMD’s content recommendation engine, an innovative content marketing solution, delivered 450,000 article readers last month

TrendMD's exponential network growth since May 2015. The company's platform has made 95 million article recommendations to its 12 million readers in the last month alone.
TrendMD’s exponential network growth since May 2015. The company’s platform has made 95 million article recommendations to its 12 million readers in the last month alone.

Faced with the challenge of finding research they need across a staggering and ever-growing number of articles online, researchers and clinicians are clicking on personalized article recommendations delivered by TrendMD’s recommendation widget.

TrendMD is a graduate of the UTEST program’s third cohort.

Using sophisticated algorithms across millions of articles served each month, recommended articles are identified based on keywords and user behaviour, such as click behaviour (“people that read X, also clicked on Y”), article popularity, and personalization (what the specific visitor has read on past visits to the network). From an article page with the TrendMD widget, readers get direct links to recommended articles either from within that publisher, or from a third-party publisher — exactly at the moment they are engaged in research– saving time and increasing awareness of relevant research they may not have discovered with a keyword search.

“Since launch, each week we have consistently increased viewers reached by at least 5%. We’re now generating over 95 million recommended articles to approximately 12 million readers per month. Of the people we reach, we’ve delivered over 450,000 readers to publishers in the network. As we continue to grow the TrendMD network, we retain readers longer and increase new traffic for our publishers. We’ve invested in infrastructure to prepare for significant growth in partnerships. We recently indexed over 1 million articles from Wolters Kluwer and began delivering readers to more articles right from the point our recommendation software went live,” said Paul Kudlow, co-founder of TrendMD.

MI_trendmdIngentaconnect recently added 96 journals from 32 publishers to the TrendMD network. Byron Russell, head of Ingentaconnect at Publishing Technology explains, “Each month we direct thousands of readers to our publishing clients’ content and add value by enhancing their research experience. Partnering with TrendMD is an innovative way of delivering more value to both readers and publishers. Readers get highly targeted recommendations for further research, and our publishers’ articles get significantly greater visibility through TrendMD’s growing network.”

In the past month, TrendMD’s recommendation widget was added to over a million articles across hundreds of journals from leading STM publishers such as Wolters Kluwer, Elsevier, Nature Publishing Group, and others. TrendMD’s network is a growing list of the world’s leading research publishers which includes BMJ Group, IEEE (EMBS), MDPI, and Rockefeller University Press. The article recommendation widget is featured across more than 70 publishing partners and is viewed by nearly 12 million readers per month.

“Science, medicine, nursing, and allied health are strengths of our publishers’ network. We can deliver specific article recommendations personalized to a cardiologist’s interests, for example. Articles are identified based on what the user is reading at the moment and what he or she and others also clicked on from within the TrendMD widget across visits to network publishers’ articles,” Paul Kudlow commented.

Continue Reading

Crowdmark successfully pilots two-stage exams in North America

Crowdmark's two-stage exam interface.
A screenshot of Crowdmark’s two-stage exam interface.

TORONTO, Oct. 21, 2015 – Working with five leading universities in North America during 2014-15, Crowdmark Inc., a collaborative online grading and analytics platform, has demonstrated the benefits and advantages of using two-stage examinations in a number of undergraduate programs in post-secondary institutions across the world.

Crowdmark has worked with universities to introduce two-stage exams as a way to integrate collaborative learning and assessment into the traditional exam format. In a two-stage exam, students individually complete the exam and then, working in groups of three to four, immediately complete the exam again. This method provides students with immediate feedback through discussion with their peers as they deliberate the most correct response. The two-stage exam provides feedback on individual performance while increasing students’ engagement and comprehension of course content.

James Colliander, Crowdmark Founder/CEO and Professor of Mathematics at the University of British Columbia is encouraged by the reception two-stage exams have received at universities in North America.

“The experiments with two-stage exams last spring were very informative and helped shape our platform to support a new and emerging assessment scenario,” says Colliander. “Also with feedback from our customers, we made elegant improvements allowing Crowdmark to be used for other assessment types including lab reports and group projects.”

Continue Reading

Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline

Encycle TherapeuticsTORONTO, ON (September 30, 2015) — Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.

This news was covered in PEHub, BetaKit and TechVibes.

The funding will support ongoing development of Encycle’s unique nacellin platform chemistry and advance the company’s pipeline of novel therapeutics. It will also allow the company to build on research collaborations with several pharmaceutical companies and ultimately position it for a series A transaction and/or additional strategic partnerships.

“Our proprietary chemistry has the potential to unlock myriad therapeutic avenues, including via intracellular protein-protein interactions that cannot be targeted with conventional therapeutics,” said Dr. Jeffrey Coull, president and CEO of Encycle Therapeutics; upon the closing, Coull joined Encycle’s board of directions. “This funding is critical to enable the company to further explore the vast potential of our technology and to de-risk it to the extent that major transactions will be enabled.”

“Our goal is to make an impact on patients’ lives by turning science and technology into life-changing medicines. We are enthusiastic about Encycle’s technology and its potential in the context of ‘undruggable’ proteins,” said Dr. Ilan Zipkin, senior investment director at Takeda.

“Encycle’s growing momentum reflects MaRS Innovation’s efforts to shift the Canadian paradigm for technology transfer,” said Dr. Raphael Hofstein, chairman of the Encycle Therapeutics Board of Directors and president and CEO of MaRS Innovation. “This company began with promising research in Dr. Andrei Yudin’s laboratory at the University of Toronto. With crucial support from many players along the Ontario-Quebec life sciences corridor, MaRS Innovation collaborated with him to package and protect the technology, launch the company and hire experienced management. The success of this funding round bodes well for its future growth and success.”

Continue Reading

Financial Post covers Onyx Motion’s Swish app, scheduled to launch in November

Company plans future sports applications for tennis and golf for its Motion Marketplace

Onyx product shotSwish by Onyx Motion “takes advantage of motion sensors to provide accurate tips and feedback to improve play,” wrote Robert Liwanag in “App for smartwatches helps users become better basketball players” for the Financial Post‘s “Entrepreneur” section on September 28, 2015.

“Using it is simple — you turn it on, press calibrate and lift your arms and hands as you would to shoot a basket,” wrote Liwanag. “The objective is to bring the circle hovering inside the target on the watch’s screen to go green. When it does, the user is in the right starting position and has the ability to achieve consistency shot after shot.”

Onyx Motion is a graduate of the UTEST program‘s third cohort (and is currently based in Ryerson’s Digital Media Zone). Their basketball app, which is scheduled to launch in November after a successful Indiegogo campaign, is the first of several sports-focused products planned by CEO Marissa Wu.

Continue Reading

Triphase announces Health Canada approval to initiate Marizomib Phase 1 study in recurrent glioma patients

Triphase-logo-WebTORONTO and SAN DIEGO (September 25, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal transduction, which inhibits tumor growth.

The study will be conducted in Canada at the Princess Margaret Hospital in Toronto and led by principal investigator Warren Mason, M.D., medical director of the Brain Tumour Centre and Kirchmann Family Chair in Neuro-oncology Research at Princess Margaret Hospital.

“Malignant gliomas are rarely curable, and the prognosis for patients with high-grade gliomas is generally poor. One of the few treatment options currently available for recurrent gliomas is bevacizumab. As a result, new treatment options are urgently needed for patients suffering from this universally fatal disease,” said Dr. Mason. “Published literature indicates that targeting the proteasome in glioma cells has shown significant anti-tumor activity. Given that marizomib is a first-in-class pan-proteasome inhibitor that is brain penetrant, I am looking forward to evaluating this combination regimen in my patients.” 

Continue Reading

TD announces exclusive Canadian agreement with Flybits

Companies to collaborate on creating enhanced personalized mobile experiences for TD customers

Flybits corporate logo 2015TORONTO, Sept. 16, 2015 — TD Bank Group and Flybits today announced an exclusive agreement within the Canadian financial services industry to collaborate on providing TD customers with more personalized mobile banking experiences.

This announcement was covered in Forbes, BetaKit, TechVibes, IT Business.ca, Marketing Magazine, CAN Tech Letter and Strategy online.

The Flybits cloud-based software program transforms mobile apps to deliver rich, contextual experiences to each user, including personalized financial advice—where and when they need it.

Flybits is a Ryerson University start-up created in partnership with MaRS Innovation. Read more about their growth and development in our news archive.

“A key focus for TD’s digital roadmap is to create more intuitive, personalized experiences that make customers’ lives simpler,” said Rizwan Khalfan, senior vice president and chief digital officer, TD. “Our agreement with Flybits is another example of TD demonstrating its commitment to enriching customers’ lives through innovation. We’re elevating our customer-centric approach by bringing in-the-moment experiences to each individual depending on their situation and needs.”

Continue Reading

UTEST company Nvest listed in Omers’ Canadian #FinTech Infographic

Nvest Logo“Over the past few weeks, a few members of our investment team took the seopportunity to map out FinTech companies from coast-to-coast, focusing on those that are developing next generation technologies or technology enabled services,” wrote the OMERS Venture team in a blog post accompanying a new #fintech infographic that lists 89 Canadian businesses operating in the financial start-up sector.

Nvest, part of the third UTEST cohort, in included in the graphic (see below). The infographic’s release was also covered in BetaKit in a story by Doug Soltys noting the sector’s growth in just six months:

What a difference six months makes. Today, Canadian VC giant OMERS Ventures released a similar infographic, tracking 89 different Canadian FinTech startups from Vancouver to St. John’s, essentially a 40 per cent increase. OMERS also noted that these 89 companies have attracted over $1 billion in capital since 2010.

Here’s where OMERS Ventures’ take on where the sector going:

Continue Reading

My Virtual Dream publishes PLOS study on Nuit Blanche results

“My Virtual Dream” is an innovative and interactive live performance experience of the Virtual Brain technology developed by researchers at Baycrest Health Sciences Centre in partnership with neuroscience experts around the world.

Baycrest Heath Sciences’ “My Virtual Dream,” an innovative and interactive live performance experience at the intersection of science, art and music, is currently touring the installation with appearances in Amsterdam in May and more scheduled for Irvine, CA in October.

MaRS Innovation is working with the Baycrest team to commercialize the technology behind the demonstration, known as the virtual brain.

My Virtual Dream was featured in TechVibes on July 8 and in a PLOS blog published on August 14, 2015.

“The Virtual Dream tour is a ‘living lab’ that engages the public, fuels science, creates art and educates while it entertains,” says Richard Tavener, executive producer of the Virtual Dream tour.

The exhibition and research project was originally mounted in partnership with the University of Toronto, Nuit Blanche 2013, and InteraXon and also made a January 2015 appearance at the Ontario Science Centre.

Participants wear the Muse, a brain-computer interface headset provided by InteraXon, and use focus and mental relaxation states to complete a science game and create a stunning array of visuals and music.

The brain data collected at Nuit Blanche has yielded insights about how the brain learns and a science paper about this massive, one-night neuroscience experiment. The paper, which appeared in the July issue of PLOS One, found that:

Continue Reading

LegWorks takes top spot at Parapan Am accessibility tech pitch contest

BresoTec, formerly known as ApneaDx, also among top five finalists

LegWorks LogoTORONTO, August 11, 2015 – Legworks‘ next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.

Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS Discovery District from August 8 to 10, 2015.

TechVibes and Metro News covered this announcement.

Legworks was one of five companies to make it to the final round of the competition.

BresoTec company logoOther finalists were Eightfold Technologies, MyndTec, BresoTec Inc., and Komodo OpenLabs. BresoTec Inc., formerly known as ApneaDx Inc., is a MaRS Innovation start-up company spun-off in partnership with the University Health Network’s Toronto Rehabilitation Institute and is developing a medical device to allow patients to determine whether they have sleep apnea without having to visit a sleep clinic.

Continue Reading

Law firm partners with UTEST program to offer legal advice to early-stage startups

TORONTO, ON (August 10, 2015) — Toronto-based law firm Aird & Berlis LLP (A&B) has become the sponsoring legal partner to the University of Toronto Early-Stage Technology Program (UTEST).

This partnership was covered in TechVibes, Law Times and the Financial Post‘s Legal Post blog.

Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.
Welcome to the table: Aird & Berlis are joining MaRS Innovation and the University of Toronto in supporting UTEST, an early-stage incubator for start-up companies that has graduated 17 companies and counting.

UTEST is a 12-month incubation and acceleration program co-managed by the University of Toronto (U of T) and MaRS Innovation that allows selected U of T-affiliated early-stage startup companies to incorporate, use office space, receive mentorship and access $30,000 in funding, with opportunities for follow-on funding from MaRS Innovation.

In 2014, UTEST was named one of Canada’s most promising start-up accelerators in an online series by BetaKit, a digital publication that covers Canadian technology.

“We are thrilled to partner with A&B and leverage their legal expertise for our startups and emerging companies,” said Kurtis Scissions, who co-directs UTEST with MI’s Mike Betts. “To date, 17 companies, including Granata Decision Systems, Whirlscape, Crowdmark, eQOL and TrendMD, have successfully graduated from our program. We look forward to adding A&B’s Startups Team of lawyers to our mentorship group for the UTEST program, beginning in 2015.”

Continue Reading
Back To Top